echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Drugs Articles > The market for innovative drugs is accelerating, and the proportion is expected to increase from 21% to 50% in the future.

    The market for innovative drugs is accelerating, and the proportion is expected to increase from 21% to 50% in the future.

    • Last Update: 2020-11-20
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Pharmaceutical Network Market Analysis: It is well known that the development of innovative drugs is a long process, the time, energy, and risks faced are very large.
    but it can bring tremendous benefits to society and patients.
    now, as the third batch of collections advances, it means the beginning of normalization of collections.
    the entire pharmaceutical market landscape is facing changes, the domestic generics market has been driven by sales to cost-driven and market access-driven, generics industry threshold further increased, market concentration has increased.
    background, the industry believes that the domestic innovative drug market will usher in new development opportunities.
    In addition, in recent years, the optimization and adjustment of the medical insurance structure, auxiliary drug give way, green approval channel, the introduction of science and technology board and other measures, continued to release a clear signal to support innovation, will help domestic innovative drug research and development continue to accelerate, innovative pharmaceutical companies are expected to take advantage of the policy east wind and domestic drug structure optimization opportunities, ushered in a golden period of development.
    2019 Drug Review Report issued by the State Drug Administration shows that in 2019, the Drug Review Center accepted a total of 700 applications for registration of one class of innovative drugs (319 varieties), an increase of 20.8% over 2018;
    as the market for innovative drugs accelerates, so is the commercialization of innovative drugs.
    years, more and more innovative drugs have been negotiated into the health-care list.
    70 new drugs are included in the 2019 health-care catalog, mostly new drugs that have been released in recent years with high clinical value, sending a clear signal of support for drug innovation.
    addition, the growing maturity of DTP pharmacies also provides a new channel for the commercialization of innovative pharmaceuticals, which is attracting more and more innovative pharmaceutical companies as the esoeric advantages of DTP pharmacies become apparent.
    , capital markets are also bullish on the innovation drug circuit.
    For example, China Life Security Fund believes that although the current pharmaceutical industry into a short-term correction, but combined with the current current situation of the environment, domestic innovative drugs are expected to become a blue sea in the sunrise industry.
    suggested that investors could focus on funds with innovative drugs as their main investment direction.
    Some investors also pointed out that, referring to the NASDAQ index from 2000 to the present, pharmaceutical stocks accounted for 20% of the top 50 stocks, 90% of which are innovative drugs and innovative devices, the Chinese market is entering such an era, the next decade is a good time to invest in pharmaceutical innovation.
    understood that China's innovative drugs in the entire pharmaceutical market accounted for only 21%, which also means that the development potential of innovative drugs is huge.
    industry believes that the future of the Chinese market for innovative drugs, the proportion of sales of original research drugs will be increased, enterprises will gradually focus on innovative drug production and research and development.
    china's future pharmaceutical market, more than 50% will gradually be transformed into innovative drugs, forming a very important trend.
    While new drug research and development is gradually recognized by the market, new drug research and development outsourcing enterprises will be able to provide pharmaceutical companies with specialized outsourcing services at all stages or at the full stage of the new drug research and development industry chain, effectively reducing the cost of research and development and research and development cycle, improve their research and development efficiency.
    , the future of new drug research and development outsourcing industry will also usher in good development opportunities.
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.